Skip to content

Rezvan Ameli

National Institutes of Health, National Institutes of Health Clinical Center

6 papers in the library · 4,734 citations · publishing 2006-2025

Papers

Sort Most recent Most cited

Effects of a combined nature-based and audio-based virtual mindfulness intervention on stress and wellbeing of COVID-19 healthcare workers: a randomized controlled trial.

PeerJ 2025 Polycarpe Bagereka, Rezvan Ameli, Ninet Sinaii et al.

The global COVID-19 pandemic and its subsequent transition to an endemic phase has highly increased psychosocial distress among healthcare workers. This chronic stress may culminate into burnout, which has been associated with impaired patient care and increased medical errors. Exposure to nature-based programs have been shown to reduce levels of perceived stress and promote well-being....

Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder

Cancer December 18, 2023 Manish Agrawal, Yvan Beaussant, Sarah Shnayder et al. 73 citations

Abstract Background Depression is common in patients with cancer and is associated with lower treatment adherence and reduced quality of life. Antidepressants and psychotherapy have limited success in improving depression among patients with cancer. This study explored the safety, feasibility, and efficacy of psilocybin‐assisted therapy in patients with cancer and major depressive disorder....

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.

Journal of Affective Disorders February 15, 2023 Sarah Shnayder, Rezvan Ameli, Ninet Sinaii et al. 67 citations

While psychedelics have been shown to improve psycho-spiritual well-being, the underlying elements of this change are not well-characterized. The NIH-HEALS posits that psycho-social-spiritual change occurs through the factors of Connection, Reflection & Introspection, and Trust & Acceptance. This study aimed to evaluate the changes in NIH-HEALS scores in a cancer population with major...

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

Translational Psychiatry October 14, 2014 Níall Lally, Allison C. Nugent, David A. Luckenbaugh et al. 269 citations

Anhedonia--which is defined as diminished pleasure from, or interest in, previously rewarding activities-is one of two cardinal symptoms of a major depressive episode. However, evidence suggests that standard treatments for depression do little to alleviate the symptoms of anhedonia and may cause reward blunting. Indeed, no therapeutics are currently approved for the treatment of anhedonia....

Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder

The Journal of Clinical Psychiatry July 13, 2010 Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché et al. 563 citations

OBJECTIVE: Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major...

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

Archives of General Psychiatry August 1, 2006 Carlos A. Zarate, Jaskaran Singh, Paul J. Carlson et al. 3,762 citations

CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the...